Regulus Therapeutics

Regulus Therapeutics Inc. is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. @regulusrx

[Regulus Therapeutics @RegulusRx]

Connecting you with us - $RGLS is continuing to push the #microRNA envelope forward. Check out our new website at https://t.co/8lugZt7nWy

[Regulus Therapeutics @RegulusRx]

$RGLS interim data on RG-101 for the tx of #HCV shows significant virologic responses through 24 weeks of follow-up https://t.co/Lk6qoWAfGc

[Regulus Therapeutics @RegulusRx]

“The data strengthens our conviction in the clinical utility of RG-101 to shorten oral #HCV tx regimens to 4 wks or less” $RGLS CEO Grint

[Regulus Therapeutics @RegulusRx]

$RGLS announces top-line results from primary endpoint analysis of Ph 2 RG-101 for the tx of #HCV. Read more: https://t.co/Lk6qoWiEOE

[Regulus Therapeutics @RegulusRx]

Tune in at 5pm ET as $RGLS management talks 2016 Q1 results, RG-101, RG-012 and #microRNA pipeline. Listen here: https://t.co/8Kz2ORSviU

[Regulus Therapeutics @RegulusRx]

Lots to come in 2016 – updates on RG-101 in #HCV, RG-012 Ph2 study in #AlportSyndrome, & nomination of potential 4th #microRNA candidate

[Regulus Therapeutics @RegulusRx]

“2016 is shaping up to be a pivotal year for $RGLS. RG-101 remains a focus with potential to be a backbone of #HCV treatment” CEO Paul Grint

[Regulus Therapeutics @RegulusRx]

$RGLS reports 2016 Q1 financial results as well updates on RG-101 in #HCV, RG-012 in #AlportSyndrome & pipeline https://t.co/9fxsrSRltI

[Regulus Therapeutics @RegulusRx]

Today, $RGLS CEO Paul Grint will be speaking on emerging anti-viral agents at the FBR Healthcare Series at 11:30am ET in NYC.

[Regulus Therapeutics @RegulusRx]

Thanks for the great time #ILC2016 and Barcelona! It was exciting to hear new #research & discoveries from #liver experts.

[Regulus Therapeutics @RegulusRx]

RG-101, in combo w/ approved anti-viral agents, shows continued high response rates supporting 4 wk #HCV tx #ILC2016 https://t.co/Mzp3CTS1O7

[Regulus Therapeutics @RegulusRx]

The data supports the potential of RG-101 to be a backbone agent in combination w/ all classes of oral #HCV therapies. ~ $RGLS CEO #ILC2016

[Regulus Therapeutics @RegulusRx]

$RGLS interim Ph2 data @ #ILC2016 shows continued high response rates to RG-101 through 24 weeks in #HCV patients https://t.co/HPydq8lUrG

[Regulus Therapeutics @RegulusRx]

$RGLS is highlighted as part of the #ILC2016 press program! Check out RG-101 potential Tx for #HCV https://t.co/2BR0kgaF8B

[Regulus Therapeutics @RegulusRx]

Dr. Femke Stelma, a key investigator in our new RG-101 data, will be speaking at #ILC2016’s Early Morning Workshop tomorrow at 7:30am CET!

[Regulus Therapeutics @RegulusRx]

We are pleased to be a part of the #ILC2016 press program, showcasing our new #data on RG-101 for the tx of #HCV. Stay tuned for more info!

[Regulus Therapeutics @RegulusRx]

$RGLS is giving an oral presentation on the latest RG-101 data at #ILC2016 at 8:45am CET tomorrow. More info here: https://t.co/bsvU2LwWTP

[Regulus Therapeutics @RegulusRx]

HCV tx can take months. Further updates on $RGLS shortened regimen at #ILC2016!

[Regulus Therapeutics @RegulusRx]

$RGLS is headed to Barcelona! ✈ Thrilled to be a part of the #HCV conversation at #ILC2016. Stay tuned for updates & new data on RG-101

[Regulus Therapeutics @RegulusRx]

#Fact: #HCV is a worldwide issue. 🌎 130-150 million people globally have chronic #HCV infection. More here: https://t.co/D9MFIADUJk #ICL2016